Connect your AI

Kura Oncology KURA Operating lease liabilities

Operating lease liabilities at other companies

Corvus PharmaceuticalsCRVS

——

SELLAS Life Sciences Group, Inc.SLS

——

Bicara TherapeuticsBCAX

——

Ethos Technologies, Inc. LIFE

——

Other financials

Income statement

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

Operating cash flow-$85.9M-19.4%

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation

Market cap$919.7M+81.6%

Enterprise value$904.89M+90.7%

P/S12.8×+3.5×

Profitability

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

FCF margin130.6%+74.1pp

Returns & leverage

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Kura Oncology's operating lease liabilities?: Kura Oncology (KURA) reported operating lease liabilities of $3.78M in Q1 2026.